SCC244 (glumetinib), a highly selective c-Met inhibitor, was granted breakthrough therapy designation by the China National Medical Products Administration (NMPA) for the treatment of patients with MET ex14Δ-positive metastatic or advanced NSCLC in 2021 (No. CXHB1600071) and orphan drug designation by the FDA for treatment for NSCLC with MET genomic aberration in 2022 (https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=858221). This evidence concerns the gene MET and non-small cell lung carcinoma.